The seven-figure equity round was led by Insurtech Gateway with backing from the Development Bank of Wales.
"Coincover helps crypto businesses to address the security concerns of the cautious investor and delivers the trust mark they need to stand out in a crowded and wary market. We are the only company in the world with a security product that is backed by Lloyds of London, providing protection from cryptocurrency theft at the individual level and an opportunity to maximise business revenue by enabling our partners to build systems that creates strong trust with their clients."
Epidarex Capital led the seed round to help the Edinburgh spin-out advance its tumour-associated macrophage platform.
"Decades of research into macrophage biology, particularly that of tumour-associated macrophages, have made it very clear to me that this is an area of significant untapped potential for the development of novel cancer therapeutics. The creation of Macomics based on the research of my group at the University of Edinburgh provides the team with an exciting opportunity to develop new effective cancer drugs against macrophage targets, that will bring real clinical benefit to many more patients suffering from cancer."
— Jeffrey Pollard, Director of the MRC Centre for Reproductive Health at the University of Edinburgh
The £10m Series A investment was led by Sandton Capital Partners to accelerate global expansion and product development.
"Our success in driving and evolving the dash cam category over the past five years has given us a very strong, market-leading position on which to build further. We have grown our business to date without external funding and as dash cams increasingly become an essential part of everyday driving we feel it is time to accelerate our plans. We see this investment as the route to expedite the roll-out of our cutting edge proprietary technology and our territory expansion, bringing this innovative technology to all drivers globally."
The seed round was led by Meltwind and Start Codon to accelerate in vivo proof-of-concept studies.
"Incorporation of our technology into ADC products will accelerate and energise the important transition away from the 'one size fits all' approach currently being pursued in ADC development, resulting in novel products with a competitive and differentiated profile. The platform has the power to unlock the development of a new generation of powerful and well-tolerated drugs, which have been so far inaccessible to many cancer patients."
